DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. METHODS: This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T>MIC) and 100% (100% f T>MIC) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. RESULTS: We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48-73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14-24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T>MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P = .009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T>MIC ratios (OR, 1.02 and 1.56, respectively; P < .03), with significant interaction with sickness severity status. CONCLUSIONS: Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association (167,(171)(172)(173).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [171]
In the citing paper
“Antibiotics are subject to changes in PK/PD parameters in sepsis and septic shock where resultant concentrations may be too low risking clinical failure, or too high leading to toxicity (Table 3) [237–239].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [238]
Citations
Cites
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376 · cited 1×
“Various demographic and clinical data were collected including age, sex, height, weight, presence of renal replacement therapy, and measures of organ function and levels of patient sickness severity as described by the APACHE II (Acute Physiology and Chronic Health Evaluation II) score [15] on admission and SOFA (Sequ…”
MethodKumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial…”
BackgroundAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundHarbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464 · cited 2×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundResultSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414 · cited 1×
“These patients may have augmented renal clearances needing either higher doses or more frequent dosing to overcome increased drug elimination [22, 23].”
BackgroundSelf-citationAntibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408 · cited 2×
“It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6].”
Background
Cited by
Items 601–700 of 1,000
Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series
Cies, J. J., Moore, W. S., Enache, A., & Chopra, A. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2330 · Cited by 9
“5, 12, [26] [27] [28] The concept of replacing "approved dose" with "approved concentrations and exposures" and tailoring dosing regimens to individual patients considering inter-and intra-patient variability across populations is profound.”
BackgroundLew, A. K., Crass, R. L., & Eschenauer, G. A. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019890346 · Cited by 9
Pneumonia: Drug-Related Problems and Hospital Readmissions
Nguyen, K. T., Pham, S. T., Vo, T. P. M., Duong, C. X., Perwitasari, D. A., Truong, N. H. K., Quach, D. T. H., Nguyen, T. N. P., Duong, V. T. T., Nguyễn, M. P., et al. (2021) · Infectious diseases · doi:10.5772/intechopen.100127 · Cited by 9
Liebchen, U., Weinelt, F. A., Scharf, C., Schroeder, I., Paal, M., Zoller, M., Kloft, C., Jung, J., & Michelet, R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01831-21 · Cited by 9
Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
Zahr, N., Urien, S., Llopis, B., Noé, G., Tissot, N., Bihan, K., Junot, H., Marin, C., Mansour, B., Luyt, C. E., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122786 · Cited by 11
“Positive clinical outcome was associated with increasing 100% fT>MIC ratio in infected critically ill patients [17].”
BackgroundChastain, D. B., Covert, K. L., Tu, P. J., McDougal, S., White, B. P., & Cluck, D. B. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231158809 · Cited by 10
Personett, H. A., Larson, S. L., Frazee, E. N., Nyberg, S. L., & Zoghby, Z. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1618 · Cited by 9
“suboptimal concentrations of such drugs can negatively impact patient outcomes.(2) Piperacillin/tazobactam (Zosyn; Pfizer Inc.”
BackgroundAbdul-Aziz, M. H., Shekar, K., & Roberts, J. A. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.07.005 · Cited by 9
Self-citationBeijer, G., Clarin, L., Östervall, J., Barclay, V., & Eliasson, E. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001016 · Cited by 8
Evaluation of pharmacokinetic pharmacodynamic target attainment of meropenem in pediatric patients
Alsultan, A., Aldawsari, M. R., Alturaiq, N. K., Syed, S. A., Alsubai, A., Kurdee, Z., Alsubaie, S., Alqahtani, S., & Abouelkheir, M. M. (2024) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2023.09.008 · Cited by 8
Sutter, P. D., Hermans, E., Cock, P. A. J. G. D., Bocxlaer, J. V., Gasthuys, E., & Vermeulen, A. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01394-z · Cited by 8
“Traditionally, the pharmacokinetic (PK)/pharmacodynamic modelling of antibiotics primarily utilises the (unbound) plasma concentration as input for these metrics [3].”
Naicker, S., Roberts, J. A., Cheng, V., Parker, S. L., Seaton, R. A., Gilchrist, M. J., & Sime, F. B. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae186 · Cited by 8
Self-citationAl‐Shaer, M. H., Maranchick, N. F., Maguigan, K. L., Shoulders, B. R., Mousa, M. J., Murray, M., Ashton, J., Alexander, K. M., Santevecchi, B. A., DeSear, K., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14050463 · Cited by 8
Dräger, S., Minichmayr, I. K., Alipanah, N., Barreto, E. F., Bos, L. D. J., Fleuren, L. M., Hunfeld, N., Mathew, S. K., STOCKER, S. L., Telles, J. P., et al. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70185 · Cited by 8
“4,5 Low antibiotic exposure may be associated with clinical and microbiologic failure, while excessive antibiotic exposure increases the risk of toxicity.”
Self-citationTarget controlled infusion in the intensive care unit: a scoping review
Introna, M., Carozzi, C., Gentile, A., Girasole, R., Gemma, M. F., Koomen, J. V., Struys, M. M. R. F., & van den Berg, J. P. (2025) · Journal of Clinical Monitoring and Computing · doi:10.1007/s10877-025-01356-1 · Cited by 8
“These factors contribute to significant inter-and intra-patient variability in drug exposure, often leading to subtherapeutic or supratherapeutic levels despite adherence to standard dosing regimens [24].”
Rimmler, C., Lanckohr, C., Mittrup, M., Welp, H. A., Würthwein, G., Horn, D., Fobker, M., Ellger, B., & Hempel, G. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14556 · Cited by 8
Lagarde, C., Bouras, M., Floch, R. L., Hourmant, Y., Grillot, N., Bourdiol, A., Mahe, P. J., Latte, D. D. D., Grégoire, M., Dailly, É., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad094 · Cited by 8
Chang, J. H. T., Liu, J., Al‐Shaer, M. H., Venugopalan, V., Maranchick, N. F., Peloquin, C. A., Rhodes, N. J., & Scheetz, M. H. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad211 · Cited by 8
Tebano, G., la Martire, G., Raumer, L., Cricca, M., Melandri, D., Pea, F., & Cristini, F. (2023) · Antibiotics · doi:10.3390/antibiotics12121737 · Cited by 8
Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients
You, X., Dai, Q., Hu, J. Y., Yu, M., Wang, X., Weng, B., Cheng, L., & Sun, F. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.01.004 · Cited by 8
Laiseca, L. B., Trocóniz, I. F., Grau, S., Campillo, N., Padilla, B., Fernández, S. N., Slöcker-Barrio, M., Herrera, L., & Santiago, M. J. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01729-23 · Cited by 8
Bahnasawy, S. M., Parrott, N. J., Gijsen, M., Spriet, I., Friberg, L. E., & Nielsen, E. I. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107352 · Cited by 8
Tseng, Y.-J., Tai, C.-H., Chen, G., Chen, Y., Ku, S., Pai, T.-Y., & Wu, C. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251320414 · Cited by 8
“27 Based on existing literature on the altered PKs in under-weight patients, reduced renal clearance is expected, which should theoretically result in higher target attainment rates.”
Simplification of Imipenem Dosing by Removal of Weight‐Based Adjustments
Lala, M., Brown, M. L. H., Kantesaria, B. S., Walker, B., Paschke, A. A., & Rizk, M. L. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1356 · Cited by 8
Edlinger-Stanger, M., al Jalali, V., Andreas, M., Jäger, W. R., Böhmdorfer, M., Zeitlinger, M. A., & Hutschala, D. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00679-21 · Cited by 8
“Continuous infusion of beta-lactams has been shown to increase the clinical cure rate and lower the 30-day mortality (52, 59).”
BackgroundNiibe, Y., Suzuki, T., Yamazaki, S., Uchida, M., Suzuki, T., Takahashi, N., Hattori, N., Nakada, T., & Ishii, I. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.12.017 · Cited by 8
Tait, J. R., Bilal, H., Rogers, K. E., Lang, Y., Kim, T., Zhou, J., Wallis, S. C., Bulitta, J. B., Kirkpatrick, C. M. J., Paterson, D. L., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11010101 · Cited by 8
“Critically ill patients are particularly vulnerable to such treatment failures due to physiological and pharmacokinetic changes, which may require the clinical use of higher than standard dosing regimens, including off-label dosages [11,12].”
BackgroundSelf-citationÖbrink‐Hansen, K., Pham, A. D., Bue, M., Hanberg, P., Bendtsen, M. A. F., Slater, J., Friberg, L. E., Thorsted, A., & Stilling, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03197-y · Cited by 8
Venuti, F., Gaviraghi, A., Nicolò, A. D., Stroffolini, G., Longo, B. M., Vincenzo, A. D., Ranzani, F. A., Quaranta, M., Romano, F., Catellani, E., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12071214 · Cited by 8
Lodise, T. P., Bhavnani, S. M., Ambrose, P. G., Sader, H. S., Andes, D. R., & Pogue, J. M. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae328 · Cited by 8
“However, there are clinical data that suggest that critically ill patients with gram-negative infections who achieve 50% f T > MIC with piperacillin and other β -lactams are more likely to have a positive clinical outcome [60–62].”
Dräger, S., Ewoldt, T. M. J., Abdulla, A., Rietdijk, W. J. R., Verkaik, N. J., van Vliet, P., Purmer, I. M., Osthoff, M. F., Koch, B. C. P., & Endeman, H. (2024) · Journal of Critical Care · doi:10.1016/j.jcrc.2024.154904 · Cited by 8
Heil, E. L., Lowery, A. V., Thom, K. A., & Nicolau, D. P. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1514 · Cited by 8
An overview on severe infections in Europe
Dimοpoulos, G., & Akova, M. (2016) · Intensive Care Medicine · doi:10.1007/s00134-016-4650-7 · Cited by 8
Self-citationAumento del aclaramiento de creatinina: ¿Cuánto más, mejor?
Tomasa-Irriguible, T. M. (2018) · Medicina Intensiva · doi:10.1016/j.medin.2018.02.004 · Cited by 8
Antifungal Dosing Considerations in Patients Undergoing Continuous Renal Replacement Therapy
Roger, C., Sasso, M., Lefrant, J.-Y., & Müller, L. (2018) · Current Fungal Infection Reports · doi:10.1007/s12281-018-0305-1 · Cited by 8
“To date, a substantial level of evidence has accumulated with regard to altered dosing requirement of antimicrobial agents in severely ill patients admitted to intensive care units (ICUs) [4].”
BackgroundSelf-citationPitarch, E. E., Padullés, A., Maisterra-Santos, K., Colom, H., & Sacristán, S. C. (2019) · PubMed · doi:10.7399/fh.11170 · Cited by 8
“[n (%)] 3 (5) 1 (4) 2 (6) Enterococcus faecium [n (%)] 1 (2) 1 (4) 0 Hemophilus influenzae [n (%)] 2 (3) 0 2 (6) Serratia marcescens [n (%)] 1 (2) 0 1 (3)”
Legg, A., Halford, M., & McCarthy, K. L. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa319 · Cited by 8
Kwong, A. C., O’Jeanson, A., & Khier, S. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00681-5 · Cited by 8
“Like all carbapenems, meropenem has a time-dependent antibacterial activity, meaning that maintaining a plasma concentration above the minimum inhibitory concentration (MIC) for at least 40% of the time of the dosing interval is associated with optimal bactericidal activity [7].”
BackgroundThibault, C., Moorthy, G. S., Vedar, C., Naim, M. Y., DiLiberto, M. A., & Zuppa, A. F. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003371 · Cited by 8
“While the traditional pharmacodynamic (PD) target was ƒT > MIC > 60%–74%,(2,3) recent studies show that a stricter goal of ƒT > MIC = 100% is associated with better outcomes in critically ill adults.(4,5) Cefepime is frequently used in children supported with extracorporeal membrane oxygenation (ECMO).”
BackgroundMethodKwee, F., Walker, S. A. N., Elligsen, M., Palmay, L., Simor, A. E., & Daneman, N. (2015) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v68i5.1485 · Cited by 9
“(%) of Patients* (n = 103) Age, mean ± SD (range) (years) 63 ± 18 (19–93) Sex, male 62 (60) Length of stay, median (range) (days) 43 (6–544) Serum creatinine, 63 (18–872) median (range) (μmol/L) Charlson comorbidity index, 2 (0–8) median (range) Pitt bacteremia score (PBS), 2 (0–8) median (range) Critical illness bact…”
BackgroundWaele, J. J. D., & Carlier, M. (2014) · Critical Care · doi:10.1186/cc13945 · Cited by 8
“2014 the patients are underdosed (when aiming for the most conservative target) and could link antibiotic underexposure to worse clinical outcome [2].”
BackgroundGerlach, A. T., Wenzler, E., Hunt, L., Bazan, J. A., & Bauer, K. A. A. (2019) · International Journal of Critical Illness and Injury Science · doi:10.4103/ijciis.ijciis_70_18 · Cited by 8
“The PK/PD target attainment was defined as fT>MIC greater than 60% of the dosing interval for cefepime and greater than 50% for piperacillin/tazobactam.[22]”
Quality of evidence supporting Surviving Sepsis Campaign Recommendations
Rello, J., Tejada, S., Xu, E., Solé-Lleonart, C., Campogiani, L., Koulenti, D., Ferreira‐Coimbra, J., & Lipman, J. (2020) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2020.06.015 · Cited by 10
“Individual recommendations personalised to patients with septic shock need to incorporate information from pharmacokinetic/pharmacodynamic studies, which have reported that underdosing is common in the ICU setting and validated in well-designed prospective studies [12,13].”
Self-citationContinuous β-Lactam Infusion to Optimize Antibiotic Use for Severe Sepsis. A Knife Cutting Water?
Chastre, J. E., & Luyt, C. E. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201507-1487ed · Cited by 8
β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients
Zeggil, T., & Dalton, B. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad150 · Cited by 8
Maranchick, N. F., Trillo‐Alvarez, C., Kariyawasam, V., Venugopalan, V., Kwara, A., Rand, K. H., Peloquin, C. A., & Al‐Shaer, M. H. (2023) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001144 · Cited by 7
Peng, Y., Liu, Y., Cheng, Z., Zhang, Q., Xie, F., Zhu, S., & Li, S. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s489603 · Cited by 7
Liebchen, U., Klose, M., Paal, M., Vogeser, M., Zöller, M., Schroeder, I., Schmitt, L., Huisinga, W., Michelet, R., Zander, J., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10040468 · Cited by 7
Burn Injury and Augmented Renal Clearance: A Case for Optimized Piperacillin-Tazobactam Dosing
Torian, S. C., Wiktor, A. J., Roper, S. E., Laramie, K. E., Miller, M. A., & Mueller, S. W. (2022) · Journal of Burn Care & Research · doi:10.1093/jbcr/irac138 · Cited by 7
Takyi‐Williams, J., Leino, A. D., Li, R., Downes, K. J., Zuppa, A. F., Bwint, A., Wen, B., Sun, D., Scheetz, M. H., & Pai, M. P. (2023) · Bioanalysis · doi:10.4155/bio-2023-0171 · Cited by 8
Gandéga, H., Poujol, H., Mezzarobba, M., Müller, L., Boyer, J.-C., Lefrant, J.-Y., Leguelinel, G., & Roger, C. (2024) · Journal of Critical Care · doi:10.1016/j.jcrc.2024.154828 · Cited by 7
Self-citationPharmacokinetic and Pharmacodynamic Approaches to Optimize Antibiotic Use in Neonates
Coggins, S. A., & Greenberg, R. G. (2024) · Clinics in Perinatology · doi:10.1016/j.clp.2024.10.005 · Cited by 8
Tilanus, A., Shields, R. K., Lodise, T. P., & Drusano, G. L. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf038 · Cited by 7
Cystatin C-Guided Dosing Nomogram Improves Target Attainment for Cefepime in the Critically Ill
Barreto, E. F., Scheetz, M. H., Chang, J. H. T., Mara, K. C., Fogelson, L. A., Paul, J., Jannetto, P. J., Gajic, O., Rule, A. D., & for the Beta Lactam Optimization and Outcomes Management (BLOOM) Study Group (2025) · Critical Care Medicine · doi:10.1097/ccm.0000000000006622 · Cited by 7
We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
Cotta, M. O., Roberts, J. A., & Lipman, J. (2016) · Critical Care · doi:10.1186/s13054-016-1348-8 · Cited by 7
“These results are consistent with previous data showing that ‘augmented renal clearance’ (ARC), defined as a CrCl ≥130 mL/min [2], is frequently being associated with subtherapeutic PIP concentrations, even when dosing PIP-TAZ four times daily (QID) [2, 3].”
ResultSelf-citationSafety considerations of current drug treatment strategies for nosocomial pneumonia
Ceccato, A., Giannatale, P. D., Nogas, S., & Torres, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1857362 · Cited by 7
Self-citationGlobal personalization of antibiotic therapy in critically ill patients
Lonsdale, D., & Lipman, J. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1874823 · Cited by 7
“reduced chances of successful antibiotic treatment [59].”
Self-citationde Cacqueray, N., Boujaafar, S., Bille, E., Moulin, F., Gana, I., Benaboud, S., Hirt, D., Béranger, A., Toubiana, J., Renolleau, S., et al. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000918 · Cited by 7
Hartman, S. J. F., Upadhyay, P. J., Mathôt, R. A. A., van der Flier, M., Schreuder, M. F., Brüggemann, R. J. M., Knibbe, C. A. J., & de Wildt, S. N. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac095 · Cited by 7
THE EUROPEAN SHOCK SOCIETY MEETS THE IMMUNOSEP CONSORTIUM FOR PERSONALIZED SEPSIS TREATMENT
Giamarellos‐Bourboulis, E. J., Dimοpoulos, G., Flohé, S. B., Kotsaki, A., van der Poll, T., Skirecki, T., Torres, A., & Netea, M. G. (2022) · Shock · doi:10.1097/shk.0000000000001955 · Cited by 7
“We suggest that future RCTs of immunomodulatory agents in sepsis should have stratified randomization with the following strata: (a) continuous infusion for β-lactams, (b) TDM and dosage adjustment, and (c) molecular microbiology for antimicrobial escalation or deescalation according to the antimicrobial resistance of…”
BackgroundSelf-citationPopulation Pharmacokinetic Study of Benzylpenicillin in Critically Unwell Adults
Shah, R. V., Kipper, K., Baker, E. H., Barker, C. I. S., Oldfield, I., Philips, B. J., Johnston, A. E., Lipman, J., Rhodes, A., Basarab, M., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12040643 · Cited by 7
“[4] demonstrated in an observational pharmacokinetic study of antibiotics that many critically ill patients do not achieve recognized therapeutic concentrations of these drugs and that suboptimal PK exposure of an antibiotic was associated with treatment failure.”
BackgroundResultInfluentialSelf-citationTowards adequate and automated antibiotic dosing
Janßen, A., Waele, J. J. D., & Elbers, P. (2023) · Intensive Care Medicine · doi:10.1007/s00134-023-07047-2 · Cited by 7
Grewal, A., Thabet, P., Dubinsky, S., Purkayastha, D., Wong, K., Marko, R., Hiremath, S. S., Hutton, B., & Kanji, S. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2861 · Cited by 7
“6 This is especially pertinent to patients with renal failure in the critical care setting, as it has been further demonstrated that current dosing guidelines in critically ill patients receiving renal replacement therapy (RRT) are likely inadequate.”
Background24/7 Therapeutic Drug Monitoring of Beta-Lactam Antibiotics with CLAM-2000
Khromov, T., Dihazi, G. H., Brockmeyer, P., Fischer, A., & Streit, F. (2023) · Antibiotics · doi:10.3390/antibiotics12101526 · Cited by 9
Hyun, D., Seo, J., Lee, S. Y., Ahn, J. H., Hong, S., Lim, C., Koh, Y., & Huh, J. W. (2023) · Antibiotics · doi:10.3390/antibiotics12101542 · Cited by 7
Tilanus, A., & Drusano, G. L. (2023) · Antibiotics · doi:10.3390/antibiotics12111581 · Cited by 7
Xü, Y., Tang, J., Yuan, B., Luo, X., Liang, P., Liu, N., Dong, D., Jin, L., Ge, W., & Gu, Q. (2023) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1163 · Cited by 7
Lejbman, I. A., Torisson, G., Resman, F., & Sjövall, F. (2024) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.14382 · Cited by 7
“4 However, beta-lactam concentrations may vary substantially, due to variations in in body mass index (BMI) 5,6 and altered physiology in critical illness, 7 such as larger volume of distribution 8 and augmented renal clearance.”
BackgroundJanßen, A., Bennis, F. C., Cnossen, M. H., & Mathôt, R. A. A. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09906-x · Cited by 7
“It has frequently been reported that these conventional regimens can result in considerable inter-individual variability of achieved drug concentrations [1–3].”
BackgroundGonçalves-Pereira, J., Fernandes, J., Mendes, T. F., Gonzalez, F. A., & Fernandes, S. M. (2024) · Antibiotics · doi:10.3390/antibiotics13090853 · Cited by 8
Pharmacokinetics of doripenem during high volume hemodiafiltration in patients with septic shock
Tamme, K., Oselin, K., Kipper, K., Low, K., Standing, J. F., Metsvaht, T., Karjagin, J., Herodes, K., Kern, H., & Starkopf, J. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.432 · Cited by 7
“Fraction of time over minimal inhibitory concentration (fT>MIC) for 50% of dosing interval was selected as PD target.(14) Mean serum protein binding of doripenem is around 8%(8) and this was accounted for in simulations.”
MethodMonajati, M., Ala, S., Aliyali, M., Ghasemian, R., Heidari, F., Ahanjan, M., Moradi, S., Sharifpour, A., Mojtahedzadeh, M., & Salehifar, E. (2020) · Infectious Disorders - Drug Targets · doi:10.2174/1871526520666200227102013 · Cited by 7
Kalkulierte parenterale Initialtherapie bakterieller Infektionen: Sepsis
Bodmann, K., Höhl, R., Krüger, W. A., Grabein, B., & Graninger, W. (2020) · GMS infectious diseases · doi:10.3205/id000053 · Cited by 7
Rafailidis, P. I., & Falagas, M. E. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1776113 · Cited by 8
Ewoldt, T. M. J., Abdulla, A., Hunfeld, N. G. M., Muller, A. E., Gommers, D., Polinder, S., Koch, B. C. P., & Endeman, H. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000891 · Cited by 8
Bohórquez, V. M., Docobo-Pérez, F., Valiente-Méndez, A., Delgado-Valverde, M., Cameán, M., Hope, W. W., Pascual, Á., & Rodríguez‐Baño, J. (2021) · Antibiotics · doi:10.3390/antibiotics10040348 · Cited by 7
“0625 and 256 mg/L were assessed in doubling dilutions, using EUCAST susceptibility breakpoints (susceptible ≤ 8 mg/L and resistant > 16 mg/L), and a pharmacodynamic index to predict efficacy, f TMIC ≥ 50% of the dosing interval, was used [37].”
MethodWoksepp, H., Karlsson, L., Ärlemalm, A., Hällgren, A., Schön, T., & Björn Carlsson, A. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000911 · Cited by 7
“MIC.(3) Our recently published report evaluated a Swedish intensive care unit (ICU) cohort and revealed that 45% of the patients did not reach 100% fT.”
BackgroundTime Above All Else: Pharmacodynamic Analysis of β‐Lactams in Critically Ill Patients
Landmesser, K. B., Clark, J. A., & Burgess, D. S. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1977 · Cited by 7
Pokem, P. N., Wittebole, X., Collienne, C., Rodriguez‐Villalobos, H., Tulkens, P. M., Elens, L., Françoise Van Bambeke, A., & Laterre, P. (2022) · Antibiotics · doi:10.3390/antibiotics11070898 · Cited by 7
“It might be explained by the variability and instability of the patient’s pathophysiological and biochemical characteristics over time [44,45].”
BackgroundPalayer, M., Chaussenery-Lorentz, O., Boubekeur, L., Urbina, T., Maury, É., Maubert, M.-A., Pilon, A., & Bourgogne, E. (2023) · Journal of Chromatography B · doi:10.1016/j.jchromb.2023.123685 · Cited by 7
Management of Infections with Drug-Resistant Organisms in Critical Care
Trevino, S. E., & Kollef, M. H. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.05.007 · Cited by 7
Optimising the administration of antibiotics in critically ill patients
Richards, G. A., Joubert, I., & Brink, A. J. (2015) · South African Medical Journal · doi:10.7196/samj.9649 · Cited by 8
Boliden auf der Intensivstation: Wie viel Antibiotika verbraucht Ihre Nierenersatztherapie pro Tag?
Kielstein, J. T., Kruse, A. K., Anderson, N., Vaitiekunas, H., & Scherneck, S. (2017) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-017-0303-z · Cited by 7
Bos, J. C., van Hest, R. M., Mistício, M. C., Nunguiane, G., Lang, C. N., Beirão, J. C., Mathôt, R. A. A., & Prins, J. M. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix961 · Cited by 7
“The finding of a high risk of underexposure to PEN during routine intermittent bolus dosing in a severely ill study population is of clinical importance, as recent evidence suggests that in critically ill patients, positive clinical outcome is independently associated with reaching the fT > MIC = 50% and fT > MIC = 10…”
ResultHammond, D. A., McCreary, E. K., Rech, M. A., Smith, M. N., Yeo, Q. M., Lusardi, K. T., Rhodes, N. J., Swanson, J. M., & Bland, C. M. (2019) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1084 · Cited by 7
Shinoda, R., Shinoda, Y., Ohashi, K., Matsuoka, T., Hirose, T., Sugiyama, T., & Yoshimura, T. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.03.006 · Cited by 7
Personalised antimicrobial dosing: standing on the shoulders of giants
Wallenburg, E., ter Heine, R., Schouten, J. A., & Brüggemann, R. J. M. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106062 · Cited by 8
Antimicrobial Pharmacokinetic Considerations in Extracorporeal Membrane Oxygenation
Johns, K., Eschenauer, G. A., Clark, A., Butler, S. O., & Dunham, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123554 · Cited by 7
Wessel, R. J., Rivera, C. G., Ausman, S. E., Martin, N. J., Braga, S., Hagy, N. T., Moreland-Head, L., Saleh, O. A., Gajic, O., Jannetto, P. J., et al. (2024) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzae062 · Cited by 6
Smekal, A.-K., Swartling, M., Furebring, M., Giske, C. G., Jönsson, S., Lipcsey, M., & Nielsen, E. I. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf013 · Cited by 6
Girdwood, S. T., Morales, R., Schuler, E. E., Tang, P., Diseroad, E. R., Misch, C., Engle, B., McCall, S., Murphy, M. E., Taylor, Z. L., et al. (2025) · Clinical and Translational Science · doi:10.1111/cts.70438 · Cited by 6
Barreto, E. F., McCreary, E. K., Mangalore, R. P., Girdwood, S. T., Arriola, R., Bens, C., Bonomo, R. A., Edginton, A. N., Hong, L. T., Huttner, A., et al. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70181 · Cited by 7
Self-citationMangalore, R. P., Chai, M. G., Pope, J. D., Lee, S. J., Padiglione, A. A., Diehl, A., Roberts, L., Sim, K., Rawson-Harris, P., Wicha, S. G., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-083635 · Cited by 6
Yang, J., Yu, M., Gan, Y., Cheng, L., Yang, G., Xiong, L., Liu, F., & Chen, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1511088 · Cited by 6
Vancomycin levels for Bayesian dose-optimization in critical care: a prospective cohort study
Dreyse, N., Salazar, N., Munita, J. M., Rello, J., & López, R. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1575224 · Cited by 6
Self-citationHuan, X., Hu, L., Li, H., Yu, F., & Shao, H. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107632 · Cited by 7
Avoiding resistance development to newer drugs: open research lines
Rinaldi, M., Gatti, M., & Giannella, M. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.11.009 · Cited by 6
Schouwenburg, S., Wildschut, E. D., de Hoog, M., Koch, B. C. P., & Abdulla, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.750080 · Cited by 6
“Both fT > MICECOFF and fT> 4x MICECOFF have been described in literature before as key attainment parameters (Roberts et al., 2014).”
BackgroundRohani, R., Scheetz, M. H., Donnelly, H. K., Donayre, A., Kang, M., Diaz, E., Dedicatoria, K., Hauser, A. R., Ozer, E. A., Nozick, S., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac245 · Cited by 6
He, X., Liu, X., Gong, X., Wang, L., & Chen, F. (2023) · Current Drug Metabolism · doi:10.2174/1389200224666230325121729 · Cited by 6
Metadata
- Authors
- Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., Rello, J., Rhodes, A., Starr, T., Wallis, S. C., Lipman, J., Study, D., Roberts, J. A., Lipman, J., Starr, T., Wallis, S. C., Paul, S. K., Margarit Ribas, A., De Waele, J. J., De Crop, L., Spapen, H., Wauters, J., Dugernier, T., Jorens, P., Dapper, I., De Backer, D., Taccone, F. S., Rello, J., Ruano, L., Afonso, E., Alvarez-Lerma, F., Gracia-Arnillas, M. P., Fernandez, F., Feijoo, N., Bardolet, N., Rovira, A., Garro, P., Colon, D., Castillo, C., Fernado, J., Lopez, M. J., Fernandez, J. L., Arribas, A. M., Teja, J. L., Ots, E., Carlos Montejo, J., Catalan, M., Prieto, I., Gonzalo, G., Galvan, B., Blasco, M. A., Meyer, E., Del Nogal, F., Vidaur, L., Sebastian, R., Garde, P. M., Martin Velasco, M. D. M., Zaragoza Crespo, R., Esperatti, M., Torres, A., Montravers, P., Baldesi, O., Dupont, H., Mahjoub, Y., Lasocki, S., Constantin, J. M., Payen, J. F., Martin, C., Albanese, J., Malledant, Y., Pottecher, J., Lefrant, J.-Y., Jaber, S., Joannes-Boyau, O., Orban, C., Ostermann, M., McKenzie, C., Berry, W., Smith, J., Lei, K., Rubulotta, F., Gordon, A., Brett, S., Stotz, M., Templeton, M., Rhodes, A., Ebm, C., Moran, C., Kaukonen, K.-M., Pettila, V., Dimopoulos, G., Koulenti, D., Xristodoulou, A., Theodorou, V., Kouliatsis, G., Sertaridou, E., Anthopoulos, G., Choutas, G., Rantis, T., Karatzas, S., Balla, M., Papanikolaou, M., Myrianthefs, P., Gavala, A., Fildisis, G., Koutsoukou, A., Kyriakopoulou, M., Petrochilou, K., Kompoti, M., Michalia, M., Clouva-Molyvdas, F.-M., Gkiokas, G., Nikolakopoulos, F., Psychogiou, V., Malliotakis, P., Akoumianaki, E., Lilitsis, E., Koulouras, V., Nakos, G., Kalogirou, M., Komnos, A., Zafeiridis, T., Chaintoutis, C., Arvaniti, K., Matamis, D., Chaintoutis, C., Kydona, C., Gritsi-Gerogianni, N., Giasnetsova, T., Giannakou, M., Soultati, I., Chytas, I., Antoniadou, E., Antipa, E., Lathyris, D., Koukoubani, T., Paraforou, T., Spiropoulou, K., Bekos, V., Spring, A., Kalatzi, T., Nikolaou, H., Laskou, M., Strouvalis, I., Aloizos, S., Kapogiannis, S., Soldatou, O., Bassetti, M., Adembri, C., Villa, G., Giarratano, A., Maurizio Raineri, S., Cortegiani, A., Montalto, F., Strano, M. T., Ranieri, V. M., Sandroni, C., De Pascale, G., Molin, A., Pelosi, P., Montagnani, L., Urbino, R., Mastromauro, I., De Rosa, F. G., Ranieri, V. M., Cardoso, T., Afonso, S., Goncalves-Pereira, J., Baptista, J. P., Akova, M., & Ozveren, A.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- The University of Queensland (AU)
- Ghent University Hospital (BE)
- Centre Hospitalier Universitaire de Nîmes (FR)
- University General Hospital Attikon (GR)
- Sorbonne Paris Cité (FR)
- St George's, University of London (GB)
- University of Palermo (IT)
- University of Genoa (IT)
- Hacettepe University (TR)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-14
- Volume
- 58
- Issue
- 8
- Pages
- 1072-1083
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101416655
- Cited by
- 1,090
- References
- 31
- Citations by year
- 2026: 75 · 2025: 98 · 2024: 83 · 2023: 125 · 2022: 115 · 2021: 125 · 2020: 86 · 2019: 84 · 2018: 69 · 2017: 71 · 2016: 66 · 2015: 57 · 2014: 34
- FWCI
- 55.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- HAL (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NIHR/CS/009/007)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- beta-lactam antibiotics, antibiotic dosing, critically ill patients, intensive care unit, pharmacokinetics, pharmacodynamics, free drug concentration, time above MIC, patient outcomes
- MeSH terms
- Aged, Anti-Bacterial Agents, Bacterial Infections, Blood Chemical Analysis, Female, Humans, Intensive Care Units, International Cooperation, Male, Microbial Sensitivity Tests, Middle Aged, Prospective Studies, Models, Statistical, Critical Illness, Treatment Outcome, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.